| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we have evaluated several new molecules targeting T cell negative pathways in tumor immunity. As a result, we found that several molecules, including ETBR, HVEM CD155, and Nectin-4, play important roles in patient prognosis and postoperative recurrence in some human gastrointestinal malignancies such as esophageal, colorectal, hepatocellular carcinoma, and pancreatic cancer. In addition, in animal model, simultaneous blockade of PD-1 and anti-angiogenesis induced a synergistic in-vivo anti-tumour effect. This unique therapeutic strategy may hold significant promise for future clinical application.Our findings suggested that such molecules might have therapeutic potentials through the induction of tumor-specific memory T cells.
|
